Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio

Abstract

Effective malign and benign differentiation of prostate pathologies based on noninvasive inflammation biomarkers such NLR and PLR necessitate clinical studies with larger patient series.